Nothing Special   »   [go: up one dir, main page]

ES2159851T3 - Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa. - Google Patents

Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa.

Info

Publication number
ES2159851T3
ES2159851T3 ES97912140T ES97912140T ES2159851T3 ES 2159851 T3 ES2159851 T3 ES 2159851T3 ES 97912140 T ES97912140 T ES 97912140T ES 97912140 T ES97912140 T ES 97912140T ES 2159851 T3 ES2159851 T3 ES 2159851T3
Authority
ES
Spain
Prior art keywords
amides
phosphodiestearasa
aminotiofenocarboxilic
employment
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97912140T
Other languages
English (en)
Inventor
Rochus Jonas
Pierre Schelling
Franz-Werner Kluxen
Maria Christadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2159851T3 publication Critical patent/ES2159851T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE DESCRIBEN AMIDAS DEL ACIDO AMINOTIOFEN - CARBOXILICO CON LA FORMULA (I) Y A SUS SALES FISIOLOGICAMENTE INOCUAS, EN DONDE R 1 , R 2 , R 3 , R 4 , R 5 , A Y N T IENEN LOS SIGNIFICADOS QUE SE EXPONEN EN LA REIVINDICACION 1, MUESTRAN INHIBICION DE LA FOSFODIESTERASA V Y PUEDEN UTILIZARSE PARA EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES Y EN LA TERAPIA DE LAS ALTERACIONES DE LA POTENCIA SEXUAL.
ES97912140T 1996-10-15 1997-10-08 Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa. Expired - Lifetime ES2159851T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19642451A DE19642451A1 (de) 1996-10-15 1996-10-15 Aminothiophencarbonsäureamide

Publications (1)

Publication Number Publication Date
ES2159851T3 true ES2159851T3 (es) 2001-10-16

Family

ID=7808775

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97912140T Expired - Lifetime ES2159851T3 (es) 1996-10-15 1997-10-08 Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa.

Country Status (26)

Country Link
US (1) US6143777A (es)
EP (1) EP0934301B1 (es)
JP (1) JP4243352B2 (es)
KR (1) KR100479811B1 (es)
CN (1) CN1110493C (es)
AR (1) AR009985A1 (es)
AT (1) ATE202347T1 (es)
AU (1) AU725741B2 (es)
BR (1) BR9712321A (es)
CA (1) CA2268886C (es)
CZ (1) CZ297253B6 (es)
DE (2) DE19642451A1 (es)
DK (1) DK0934301T3 (es)
ES (1) ES2159851T3 (es)
GR (1) GR3036341T3 (es)
HK (1) HK1020724A1 (es)
HU (1) HUP9904703A3 (es)
NO (1) NO991776L (es)
PL (1) PL192109B1 (es)
PT (1) PT934301E (es)
RU (1) RU2184731C2 (es)
SI (1) SI0934301T1 (es)
SK (1) SK283807B6 (es)
TW (1) TW438791B (es)
WO (1) WO1998016521A1 (es)
ZA (1) ZA979199B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727258B2 (en) * 1997-10-29 2004-04-27 King Pharmaceutical Research & Development, Inc. Allosteric adenosine receptor modulators
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
EP1087939A1 (en) * 1998-06-19 2001-04-04 Syngenta Participations AG Process for preparation of pyrimidinone derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
WO2003027093A1 (en) * 2001-09-21 2003-04-03 Smithkline Beecham Corporation Chemical compounds
ES2315430T3 (es) * 2001-10-04 2009-04-01 Smithkline Beecham Corporation Inhibidores de nf-kb.
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7196207B2 (en) * 2002-07-24 2007-03-27 Mitsui Chemicals, Inc. Method for producing 2-alkyl-3-aminothiophene derivative
US7179836B2 (en) * 2002-09-20 2007-02-20 Smithkline Beecham Corporation Chemical compounds
FR2875807B1 (fr) 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
MX2009002496A (es) * 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
RU2472791C2 (ru) * 2008-08-27 2013-01-20 КалсиМедика Инк. Соединения, модулирующие внутриклеточный кальций
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
RU2503671C1 (ru) * 2012-07-31 2014-01-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" (Z)-2-[(3-КАРБАМОИЛ-4,5,6,7-ТЕТРАГИДРОБЕНЗО[b]ТИЕН-2-ИЛ)АМИНО]-4-(4-R-ФЕНИЛ)-4-ОКСОБУТ-2-ЕНОВЫЕ КИСЛОТЫ, ОБЛАДАЮЩИЕ АНАЛЬГЕТИЧЕСКОЙ АКТИВНОСТЬЮ
RU2501795C1 (ru) * 2012-10-01 2013-12-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" N-R-АМИДЫ (Z)-2[(3-ЭТОКСИКАРБОНИЛ)-4,5,6,7-ТЕТРАГИДРОБЕНЗО[b]ТИЕН-2-ИЛ)АМИНО]-4-ФЕНИЛ-4-ОКСОБУТ-2-ЕНОВЫХ КИСЛОТ, ОБЛАДАЮЩИЕ АНАЛЬГЕТИЧЕСКОЙ АКТИВНОСТЬЮ
EP3157520B1 (en) 2014-06-23 2019-09-04 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
SI3796975T1 (sl) 2018-05-22 2024-02-29 Orsobio, Inc. Derivati sulfonilaminobenzamida
RU2722176C1 (ru) * 2019-09-06 2020-05-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (z)-2((4-r1-5-r2-3-(этоксикарбонил)тиофен-2-ил)амино)-4-оксо-4-r3-бут-2-еновые кислоты, обладающие противомикробной активностью
JP2023537271A (ja) * 2020-07-24 2023-08-31 イニファーム，インク． チオフェンｈｓｄ１７ｂ１３阻害剤とその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US5753692A (en) * 1992-02-19 1998-05-19 Industrial Technology Research Institute Medicinal thiophene compounds
US5356926A (en) * 1992-02-24 1994-10-18 Warner-Lambert Company 3-alkyloxy-, aryloxy-, or arylalkyloxy-benzo [β]thiophene-2-carboxamides as inhibitors of cell adhesion
DE4230755A1 (de) * 1992-09-14 1994-03-17 Schering Ag Verwendung von PDE-Inhibitoren bei der Behandlung von Nieren- und Ureter-Erkrankungen
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
GB9309324D0 (en) * 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
DE4317076A1 (de) * 1993-05-21 1994-11-24 Bayer Ag Benzthiophencarbonsäureamid-S-oxide
ATE175667T1 (de) * 1994-05-31 1999-01-15 Bayer Ag Aminobenzofuryl- und -thienylderivate
US5863936A (en) * 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
WO1998015545A1 (en) * 1996-10-08 1998-04-16 Eli Lilly And Company New serotonin 5-ht1f agonists
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use

Also Published As

Publication number Publication date
SK283807B6 (sk) 2004-02-03
TW438791B (en) 2001-06-07
JP2001501957A (ja) 2001-02-13
GR3036341T3 (en) 2001-11-30
NO991776D0 (no) 1999-04-14
DE19642451A1 (de) 1998-04-16
NO991776L (no) 1999-06-09
AU4945197A (en) 1998-05-11
HUP9904703A2 (hu) 2001-05-28
ZA979199B (en) 1998-05-11
WO1998016521A1 (de) 1998-04-23
AU725741B2 (en) 2000-10-19
HK1020724A1 (en) 2000-05-19
CN1110493C (zh) 2003-06-04
SK43299A3 (en) 2000-04-10
DK0934301T3 (da) 2001-10-08
EP0934301B1 (de) 2001-06-20
KR100479811B1 (ko) 2005-03-30
CN1233246A (zh) 1999-10-27
CA2268886A1 (en) 1998-04-23
CZ124099A3 (cs) 1999-07-14
PT934301E (pt) 2001-10-31
DE59703869D1 (de) 2001-07-26
PL332802A1 (en) 1999-10-11
SI0934301T1 (en) 2001-12-31
CA2268886C (en) 2008-05-20
BR9712321A (pt) 1999-08-31
PL192109B1 (pl) 2006-08-31
ATE202347T1 (de) 2001-07-15
KR20000049154A (ko) 2000-07-25
US6143777A (en) 2000-11-07
EP0934301A1 (de) 1999-08-11
RU2184731C2 (ru) 2002-07-10
CZ297253B6 (cs) 2006-10-11
JP4243352B2 (ja) 2009-03-25
AR009985A1 (es) 2000-05-17
HUP9904703A3 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
ES2159851T3 (es) Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa.
ES2192213T3 (es) Arilalquil-diazinonas como inhibidores de fosfodiesterasa iv.
ES2171543T3 (es) Composiciones administrables topicamente que contienen derivados del acido 3-benzoilfenilacetico para el tratamiento de trastornos inflamatorios oftalmicos.
ES2191192T3 (es) Tienopirimidinas.
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
ES2059880T3 (es) Utilizacion del acido estearidonico para el tratamiento de las enfermedades inflamatorias.
ES2152222T3 (es) Sulfonamidas, su preparacion y su uso como medicamento e intermedio.
NZ501277A (en) -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ES2196054T3 (es) Derivados de acido fenilacetico, procedimiento y productos intermedios para su obtencion y agentes que contienen los mismos.
ATE31243T1 (de) Verwendung von 4-aminosalicylsaeure als entzuendungshemmender wirkstoff.
LV10575A (lv) Izoksazoi-4-karbonskabes amids un hidroksialkiliden-cianetikskabes amids sos savienojumus saturosi astniecibas lidzekli un to pielietojums
ATE106867T1 (de) 13-trans-retinsäureester.
FI833062A (fi) Arakidonsyraanaloger som anti-inflammatoriska och antiallergi-medel
AR024944A1 (es) Amidas de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y su preparacion
ES2098790T3 (es) Derivados de 1,2,3,5,6,7,8,8a-octahidro-5,5,8a-trimetil-(8abeta)-6-isoquinoleinamina, su procedimiento de preparacion y su empleo en terapeutica.
ES2061546T3 (es) Compuestos quelantes de piridoxamina, quelatos de manganeso (ii) y su uso como agentes de contraste de nmri.
FI863976A0 (fi) Terapeutisk komposition.
ES2041705T3 (es) Procedimiento para la preparacion de 1-(4-hidroxi-3,5-di-terc-butil-benzoil)-homopiperazina y sus derivados.
ES2051675T3 (es) Inhibidores de protorfirinogeno y su uso en composiciones para detectar y tratar tumores.
IT1164821B (it) Benzammidi eterocicliche sostituite procedimento per la loro produzione e loro impiego come modificatori di comportamento
PA8467301A1 (es) Nuevos derivados del acido dihidroxihexanoico
SE9601677D0 (sv) New use
AR028772A1 (es) 5-aminoalquil-pirazol[4,3-d] pirimidinas
ES2125356T3 (es) Empleo de leflunomida para la inhibicion de interleuquina 8.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 934301

Country of ref document: ES